PROVECTUS BIOPHARMACEUTICALS, INC. Deferred Revenue
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) had Deferred Revenue of $57.48 thousand as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-03-26
- 2025-03-31: Deferred Revenue, Current $57.48K.
- 2024-12-31: Deferred Revenue, Current $336.11K.
- 2024-09-30: Deferred Revenue, Current $350.44K.
- 2024-06-30: Deferred Revenue, Current $460.19K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2025-03-31 | $57.48K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $336.11K 10-K · filed 2026-03-26 |
| 2024-09-30 | $350.44K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $460.19K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $715.18K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $953.25K 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.07M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.14M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.31M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.51M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.68M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.99M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.31M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.50M 10-K · filed 2023-03-30 |